$KERX Recent News Six stocks to watch 1:47 p.m
Post# of 145205
Posted On: 09/18/2014 10:07:11 AM
$KERX Recent News
Six stocks to watch 1:47 p.m. Aug. 27, 2014 - The Trading Deck
When it rains, it pours for Nasdaq leadership 12:47 p.m. March 27, 2014 - The Trading Deck
Six stocks to watch 4:27 p.m. Feb. 26, 2014 - The Trading Deck
Nasdaq extends break to less-charted territory 12:42 p.m. Dec. 2, 2013 - Michael Ashbaugh
6 movers to watch 3:08 p.m. Nov. 6, 2013 - The Trading Deck
Keryx climbs after treatment shows positive result 11:01 a.m. Nov. 5, 2013 - MarketWatch.com
Six stocks to watch for some upside 3:21 p.m. April 11, 2013 - The Trading Deck
6 gut checks before the stock market's opening bell 7:47 a.m. March 7, 2013 - Shawn Langlois
Towerstream, Vanguard and others price offerings 11:32 a.m. Jan. 31, 2013 - MarketWatch.com
6 gut checks before the stock market's opening bell 7:52 a.m. Jan. 31, 2013 - Shawn Langlois
Keryx Biopharmaceuticals up 8.5% in premarket 8:58 a.m. Jan. 29, 2013 - Steve Gelsi
Monday’s movers: Herbalife clobbered on FTC news 5:30 p.m. Jan. 28, 2013 - Sue Chang
In focus: No letup by the bulls 8:45 p.m. Jan. 23, 2013 - Lawrence G. McMillan
Keryx Biopharma rises 17% in premarket trades 8:36 a.m. Jan. 23, 2013 - Steve Gelsi
Monday’s biggest gaining and declining stocks 4:37 p.m. April 23, 2012 - MarketWatch
Monday’s biggest gaining & declining stocks 5:56 p.m. April 2, 2012 - Kate Gibson
Keryx, AEterna implode on failed drug study 11:13 a.m. April 2, 2012 - Val Brickates Kennedy
Keryx, AEterna rally ahead of study results 1:34 p.m. March 16, 2012 - Val Brickates Kennedy
Keryx , AEterna rally ahead of study results 1:32 p.m. March 16, 2012 - Val Brickates Kennedy
Top longs and shorts to watch 1:18 p.m. March 6, 2012 - The Trading Deck
SEC Slaps Biotech Hedge Fund for Short-Selling Violations 1:04 p.m. Sept. 16, 2014 - TheStreet.com
If Achillion's Hep C Nucleotide Isn't Best In Class, The Stock Is Worth Low Single Digits 8:00 a.m. Sept. 16, 2014 - Seeking Alpha
Hottest Healthcare Stocks Now – ISIS PBYI KERX HALO 1:30 p.m. Sept. 11, 2014 - InvestorPlace.com
Insider Trading Alert - DVA, DATA And KERX Traded By Insiders 10:30 a.m. Sept. 11, 2014 - TheStreet.com
Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog 11:17 a.m. Sept. 10, 2014 - Zacks.com
Keryx Biopharmaceuticals (KERX) Weak On High Volume Today 10:02 a.m. Sept. 10, 2014 - TheStreet.com
Keryx Biopharmaceuticals (KERX) Is Today's Roof Leaker Stock 1:34 p.m. Sept. 9, 2014 - TheStreet.com
Keryx's FDA Approval a Mixed Bag 7:47 a.m. Sept. 9, 2014 - Barrons.com
Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015 7:44 a.m. Sept. 9, 2014 - 247WallSt.com
Keryx Falls after Ferric Citrate's Approval with Warnings - Analyst Blog 6:05 p.m. Sept. 8, 2014 - Zacks.com
Silver Spring Networks Starts The Week Strong 1:30 p.m. Sept. 8, 2014 - TheStreet.com
Keryx Biopharmaceuticals' (KERX) CEO Ron Bentsur Discusses the approval of Ferric Citrate (Transcript) 1:18 p.m. Sept. 8, 2014 - Seeking Alpha
Keryx Biopharmaceuticals' (KERX) CEO Ron Bentsur Discusses FDA approval of Ferric Citrate (Transcript) 1:18 p.m. Sept. 8, 2014 - Seeking Alpha
Why Keryx Biopharmaceuticals (KERX) Stock Is Falling Today 11:25 a.m. Sept. 8, 2014 - TheStreet.com
Keryx Falls Victim To A Self-Fulfilling Prophecy, Creates Opportunity 10:05 a.m. Sept. 8, 2014 - Seeking Alpha
Keryx Biopharmaceuticals (KERX) Crumbles: Stock Falls by 5.5% - Tale of the Tape 8:55 a.m. Sept. 8, 2014 - Zacks.com
Analysts' Actions: AIG, Bank of America, Ford, FireEye and More 8:27 a.m. Sept. 8, 2014 - TheStreet.com
Top Analyst Upgrades and Downgrades: Altria, BofA, FireEye, Ford, J.P. Morgan, Linn Energy and More 7:51 a.m. Sept. 8, 2014 - 247WallSt.com
Keryx Bear Case Bolstered by Less-Than-Zippy 'Zerenex' Label 7:00 a.m. Sept. 8, 2014 - TheStreet.com
Keryx Finds Out That Not All FDA Approvals Are Wins 2:17 p.m. Sept. 5, 2014 - 247WallSt.com
Market Activity, Drug Approval, Upcoming Conference, and Presentation of Clinical Data - Research Reports on Jazz, Keryx, Vertex, WellPoint and GSK 9:15 a.m. Sept. 10, 2014 - PR Newswire - PRF
Biotech Stocks Under Review -- Keryx Biopharma, Sangamo BioSciences, Regeneron Pharma, Sunesis Pharma, and Idera Pharma 9:10 a.m. Sept. 9, 2014 - PR Newswire - PRF
Keryx Biopharmaceuticals, Inc. to Present at the Rodman & Renshaw 16th Annual Global Investment Conference 4:01 p.m. Sept. 5, 2014 - GlobeNewswire
Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia 11:41 a.m. Sept. 5, 2014 - Thomson Reuters ONE
Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia 11:19 a.m. Sept. 5, 2014 - GlobeNewswire
Keryx Biopharmaceuticals, Inc. Announces Second Quarter and Six Month 2014 Financial Results 7:02 a.m. Aug. 7, 2014 - GlobeNewswire
Biotech Equities Roundup -- Keryx Biopharma, Vertex Pharma, NPS Pharma, Cubist Pharma, and Idera Pharma 8:50 a.m. Aug. 6, 2014 - PR Newswire - PRF
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2014 Financial Results 8:02 a.m. Aug. 5, 2014 - GlobeNewswire
Conference Call Schedules, Publication of Study Results, and Public Offer Pricing - Research Reports on Medivation, Keryx, Amicus, AGTC and Clovis 8:50 a.m. July 30, 2014 - PR Newswire - PRF
Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology 5:01 p.m. July 24, 2014 - GlobeNewswire
Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology 5:00 p.m. July 24, 2014 - Thomson Reuters ONE
Leadership Appointments, Earnings Conference Calls, Milestone Payments, and Technical Updates - Analyst Notes on Illumina, Alexion, Incyte, Clovis and Keryx 8:10 a.m. July 17, 2014 - PR Newswire - PRF
Patent Issuance, Positive Trial Data, Recognitions, and Priority Review - Analyst Notes on Keryx, Puma, Ligand, Sagent and Enanta 7:50 a.m. June 30, 2014 - PR Newswire - PRF
Health Care Sector Equities Technical Coverage -- Research on Keryx Biopharma, Thoratec, Unilife, and VIVUS 7:10 a.m. June 30, 2014 - PR Newswire - PRF
Keryx Biopharmaceuticals Announces Issuance of Two U.S. Patents for Zerenex(TM) Covering Orally Administrable Forms of Ferric Citrate 8:31 a.m. June 18, 2014 - GlobeNewswire
Keryx Biopharmaceuticals Announces Issuance of Two U.S. Patents for Zerenex(TM) Covering Orally Administrable Forms of Ferric Citrate 8:31 a.m. June 18, 2014 - Thomson Reuters ONE
Keryx Biopharmaceuticals, Inc. to Present at the 9th Annual JMP Securities Healthcare Conference 4:30 p.m. June 17, 2014 - GlobeNewswire
Trial Results, Patient Enrollment, and Strategic Collaborations - Analyst Notes on Alnylam, Celldex, Keryx, Spectrum and MacroGenics 5:20 a.m. June 12, 2014 - PR Newswire - PRF
Keryx Biopharmaceuticals, Inc. to Present at the 35th Annual Goldman Sachs Global Healthcare Conference 8:34 a.m. June 5, 2014 - GlobeNewswire
Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma 8:30 a.m. May 30, 2014 - PR Newswire - PRF
Six stocks to watch 1:47 p.m. Aug. 27, 2014 - The Trading Deck
When it rains, it pours for Nasdaq leadership 12:47 p.m. March 27, 2014 - The Trading Deck
Six stocks to watch 4:27 p.m. Feb. 26, 2014 - The Trading Deck
Nasdaq extends break to less-charted territory 12:42 p.m. Dec. 2, 2013 - Michael Ashbaugh
6 movers to watch 3:08 p.m. Nov. 6, 2013 - The Trading Deck
Keryx climbs after treatment shows positive result 11:01 a.m. Nov. 5, 2013 - MarketWatch.com
Six stocks to watch for some upside 3:21 p.m. April 11, 2013 - The Trading Deck
6 gut checks before the stock market's opening bell 7:47 a.m. March 7, 2013 - Shawn Langlois
Towerstream, Vanguard and others price offerings 11:32 a.m. Jan. 31, 2013 - MarketWatch.com
6 gut checks before the stock market's opening bell 7:52 a.m. Jan. 31, 2013 - Shawn Langlois
Keryx Biopharmaceuticals up 8.5% in premarket 8:58 a.m. Jan. 29, 2013 - Steve Gelsi
Monday’s movers: Herbalife clobbered on FTC news 5:30 p.m. Jan. 28, 2013 - Sue Chang
In focus: No letup by the bulls 8:45 p.m. Jan. 23, 2013 - Lawrence G. McMillan
Keryx Biopharma rises 17% in premarket trades 8:36 a.m. Jan. 23, 2013 - Steve Gelsi
Monday’s biggest gaining and declining stocks 4:37 p.m. April 23, 2012 - MarketWatch
Monday’s biggest gaining & declining stocks 5:56 p.m. April 2, 2012 - Kate Gibson
Keryx, AEterna implode on failed drug study 11:13 a.m. April 2, 2012 - Val Brickates Kennedy
Keryx, AEterna rally ahead of study results 1:34 p.m. March 16, 2012 - Val Brickates Kennedy
Keryx , AEterna rally ahead of study results 1:32 p.m. March 16, 2012 - Val Brickates Kennedy
Top longs and shorts to watch 1:18 p.m. March 6, 2012 - The Trading Deck
SEC Slaps Biotech Hedge Fund for Short-Selling Violations 1:04 p.m. Sept. 16, 2014 - TheStreet.com
If Achillion's Hep C Nucleotide Isn't Best In Class, The Stock Is Worth Low Single Digits 8:00 a.m. Sept. 16, 2014 - Seeking Alpha
Hottest Healthcare Stocks Now – ISIS PBYI KERX HALO 1:30 p.m. Sept. 11, 2014 - InvestorPlace.com
Insider Trading Alert - DVA, DATA And KERX Traded By Insiders 10:30 a.m. Sept. 11, 2014 - TheStreet.com
Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog 11:17 a.m. Sept. 10, 2014 - Zacks.com
Keryx Biopharmaceuticals (KERX) Weak On High Volume Today 10:02 a.m. Sept. 10, 2014 - TheStreet.com
Keryx Biopharmaceuticals (KERX) Is Today's Roof Leaker Stock 1:34 p.m. Sept. 9, 2014 - TheStreet.com
Keryx's FDA Approval a Mixed Bag 7:47 a.m. Sept. 9, 2014 - Barrons.com
Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015 7:44 a.m. Sept. 9, 2014 - 247WallSt.com
Keryx Falls after Ferric Citrate's Approval with Warnings - Analyst Blog 6:05 p.m. Sept. 8, 2014 - Zacks.com
Silver Spring Networks Starts The Week Strong 1:30 p.m. Sept. 8, 2014 - TheStreet.com
Keryx Biopharmaceuticals' (KERX) CEO Ron Bentsur Discusses the approval of Ferric Citrate (Transcript) 1:18 p.m. Sept. 8, 2014 - Seeking Alpha
Keryx Biopharmaceuticals' (KERX) CEO Ron Bentsur Discusses FDA approval of Ferric Citrate (Transcript) 1:18 p.m. Sept. 8, 2014 - Seeking Alpha
Why Keryx Biopharmaceuticals (KERX) Stock Is Falling Today 11:25 a.m. Sept. 8, 2014 - TheStreet.com
Keryx Falls Victim To A Self-Fulfilling Prophecy, Creates Opportunity 10:05 a.m. Sept. 8, 2014 - Seeking Alpha
Keryx Biopharmaceuticals (KERX) Crumbles: Stock Falls by 5.5% - Tale of the Tape 8:55 a.m. Sept. 8, 2014 - Zacks.com
Analysts' Actions: AIG, Bank of America, Ford, FireEye and More 8:27 a.m. Sept. 8, 2014 - TheStreet.com
Top Analyst Upgrades and Downgrades: Altria, BofA, FireEye, Ford, J.P. Morgan, Linn Energy and More 7:51 a.m. Sept. 8, 2014 - 247WallSt.com
Keryx Bear Case Bolstered by Less-Than-Zippy 'Zerenex' Label 7:00 a.m. Sept. 8, 2014 - TheStreet.com
Keryx Finds Out That Not All FDA Approvals Are Wins 2:17 p.m. Sept. 5, 2014 - 247WallSt.com
Market Activity, Drug Approval, Upcoming Conference, and Presentation of Clinical Data - Research Reports on Jazz, Keryx, Vertex, WellPoint and GSK 9:15 a.m. Sept. 10, 2014 - PR Newswire - PRF
Biotech Stocks Under Review -- Keryx Biopharma, Sangamo BioSciences, Regeneron Pharma, Sunesis Pharma, and Idera Pharma 9:10 a.m. Sept. 9, 2014 - PR Newswire - PRF
Keryx Biopharmaceuticals, Inc. to Present at the Rodman & Renshaw 16th Annual Global Investment Conference 4:01 p.m. Sept. 5, 2014 - GlobeNewswire
Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia 11:41 a.m. Sept. 5, 2014 - Thomson Reuters ONE
Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia 11:19 a.m. Sept. 5, 2014 - GlobeNewswire
Keryx Biopharmaceuticals, Inc. Announces Second Quarter and Six Month 2014 Financial Results 7:02 a.m. Aug. 7, 2014 - GlobeNewswire
Biotech Equities Roundup -- Keryx Biopharma, Vertex Pharma, NPS Pharma, Cubist Pharma, and Idera Pharma 8:50 a.m. Aug. 6, 2014 - PR Newswire - PRF
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2014 Financial Results 8:02 a.m. Aug. 5, 2014 - GlobeNewswire
Conference Call Schedules, Publication of Study Results, and Public Offer Pricing - Research Reports on Medivation, Keryx, Amicus, AGTC and Clovis 8:50 a.m. July 30, 2014 - PR Newswire - PRF
Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology 5:01 p.m. July 24, 2014 - GlobeNewswire
Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology 5:00 p.m. July 24, 2014 - Thomson Reuters ONE
Leadership Appointments, Earnings Conference Calls, Milestone Payments, and Technical Updates - Analyst Notes on Illumina, Alexion, Incyte, Clovis and Keryx 8:10 a.m. July 17, 2014 - PR Newswire - PRF
Patent Issuance, Positive Trial Data, Recognitions, and Priority Review - Analyst Notes on Keryx, Puma, Ligand, Sagent and Enanta 7:50 a.m. June 30, 2014 - PR Newswire - PRF
Health Care Sector Equities Technical Coverage -- Research on Keryx Biopharma, Thoratec, Unilife, and VIVUS 7:10 a.m. June 30, 2014 - PR Newswire - PRF
Keryx Biopharmaceuticals Announces Issuance of Two U.S. Patents for Zerenex(TM) Covering Orally Administrable Forms of Ferric Citrate 8:31 a.m. June 18, 2014 - GlobeNewswire
Keryx Biopharmaceuticals Announces Issuance of Two U.S. Patents for Zerenex(TM) Covering Orally Administrable Forms of Ferric Citrate 8:31 a.m. June 18, 2014 - Thomson Reuters ONE
Keryx Biopharmaceuticals, Inc. to Present at the 9th Annual JMP Securities Healthcare Conference 4:30 p.m. June 17, 2014 - GlobeNewswire
Trial Results, Patient Enrollment, and Strategic Collaborations - Analyst Notes on Alnylam, Celldex, Keryx, Spectrum and MacroGenics 5:20 a.m. June 12, 2014 - PR Newswire - PRF
Keryx Biopharmaceuticals, Inc. to Present at the 35th Annual Goldman Sachs Global Healthcare Conference 8:34 a.m. June 5, 2014 - GlobeNewswire
Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma 8:30 a.m. May 30, 2014 - PR Newswire - PRF
(0)
(0)